GlassScriptPhysician profile
Maria L Johnson
NPI 1962422162
$6,940.66
in general payments reported to CMS, 2019-2025
35 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $2,039 · 2021: $1,093 · 2022: $14.30 · 2023: $225 · 2024: $384 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.40 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,373.94 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,331.03 | 2019-2025 | Nucala |
| Pfizer INC. | $497.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.41 | 2019-2021 | |
| Electromed, INC. | $322.37 | 2019-2025 | Smartvest |
| Csl Behring | $310.42 | 2019-2021 | |
| Insmed, INC. | $300.16 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $247.47 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $219.41 | 2019-2021 | |
| Lilly USA, LLC | $212.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $194.81 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $185.46 | 2019-2020 | |
| Optinose US, INC. | $162.71 | 2019 | |
| Pulmonx Corporation | $139.54 | 2023-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Amarin Pharma, INC. | $124.99 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.83 | 2021 | |
| Mylan Specialty L.P. | $112.73 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $90.80 | 2019 | |
| Grifols USA, LLC | $82.06 | 2019-2021 | |
| Philips North America LLC | $69.91 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.05 | 2019-2021 | |
| Gilead Sciences, INC. | $62.93 | 2021 | |
| Shire North American Group INC | $39.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.31 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.02 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.83 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.48 | 2020 | |
| Amgen INC. | $19.93 | 2025 | Tezspire |
| Olympus America INC. | $19.72 | 2021 | |
| Harmony Biosciences LLC | $19.25 | 2020 | |
| United Therapeutics Corporation | $17.80 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.70 | 2023 | Purified Cortrophin Gel |
| Vapotherm INC | $17.32 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.30 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.24 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.